309 related articles for article (PubMed ID: 29399721)
41. The endocannabinoid system and migraine.
Greco R; Gasperi V; Maccarrone M; Tassorelli C
Exp Neurol; 2010 Jul; 224(1):85-91. PubMed ID: 20353780
[TBL] [Abstract][Full Text] [Related]
42. Involvement of cannabinoid receptors in gut motility and visceral perception.
Hornby PJ; Prouty SM
Br J Pharmacol; 2004 Apr; 141(8):1335-45. PubMed ID: 15100166
[TBL] [Abstract][Full Text] [Related]
43. N-adamantyl-anthranil amide derivatives: New selective ligands for the cannabinoid receptor subtype 2 (CB2R).
Graziano G; Delre P; Carofiglio F; Brea J; Ligresti A; Kostrzewa M; Riganti C; Gioè-Gallo C; Majellaro M; Nicolotti O; Colabufo NA; Abate C; Loza MI; Sotelo E; Mangiatordi GF; Contino M; Stefanachi A; Leonetti F
Eur J Med Chem; 2023 Feb; 248():115109. PubMed ID: 36657299
[TBL] [Abstract][Full Text] [Related]
44. Cannabinoid receptors as therapeutic targets for dialysis-induced peritoneal fibrosis.
Yang CY; Chau YP; Lee HT; Kuo HY; Lee OK; Yang AH
Am J Nephrol; 2013; 37(1):50-8. PubMed ID: 23296044
[TBL] [Abstract][Full Text] [Related]
45. Functional CB2 type cannabinoid receptors at CNS synapses.
Morgan NH; Stanford IM; Woodhall GL
Neuropharmacology; 2009 Sep; 57(4):356-68. PubMed ID: 19616018
[TBL] [Abstract][Full Text] [Related]
46. Evaluation of cannabinoid CB1 and CB2 receptors expression in mobile tongue squamous cell carcinoma: associations with clinicopathological parameters and patients' survival.
Theocharis S; Giaginis C; Alexandrou P; Rodriguez J; Tasoulas J; Danas E; Patsouris E; Klijanienko J
Tumour Biol; 2016 Mar; 37(3):3647-56. PubMed ID: 26459312
[TBL] [Abstract][Full Text] [Related]
47. The Endocannabinoid System as a Therapeutic Target in Diabetic Peripheral Neuropathic Pain: A Review.
Bagher AM
J Microsc Ultrastruct; 2022; 10(2):47-54. PubMed ID: 35832317
[TBL] [Abstract][Full Text] [Related]
48. Positron Emission Tomography Imaging of the Endocannabinoid System: Opportunities and Challenges in Radiotracer Development.
Hou L; Rong J; Haider A; Ogasawara D; Varlow C; Schafroth MA; Mu L; Gan J; Xu H; Fowler CJ; Zhang MR; Vasdev N; Ametamey S; Cravatt BF; Wang L; Liang SH
J Med Chem; 2021 Jan; 64(1):123-149. PubMed ID: 33379862
[TBL] [Abstract][Full Text] [Related]
49. Targeting the endocannabinoid system in diabesity: Fact or fiction?
Deeba F; Kumar A; Mukherjee M; Sharma AK; Sharma M
Drug Discov Today; 2021 Jul; 26(7):1750-1758. PubMed ID: 33781949
[TBL] [Abstract][Full Text] [Related]
50. Polypharmacological profile of 1,2-dihydro-2-oxo-pyridine-3-carboxamides in the endocannabinoid system.
Chicca A; Arena C; Bertini S; Gado F; Ciaglia E; Abate M; Digiacomo M; Lapillo M; Poli G; Bifulco M; Macchia M; Tuccinardi T; Gertsch J; Manera C
Eur J Med Chem; 2018 Jun; 154():155-171. PubMed ID: 29793210
[TBL] [Abstract][Full Text] [Related]
51. [Role of cannabinoid receptors in renal diseases].
François H; Durrbach A; Beaudreuil S; Charpentier B; Lecru L
Nephrol Ther; 2016 Apr; 12 Suppl 1():S115-22. PubMed ID: 26968477
[TBL] [Abstract][Full Text] [Related]
52. Endocannabinoids and the renal proximal tubule: an emerging role in diabetic nephropathy.
Jenkin KA; Verty AN; McAinch AJ; Hryciw DH
Int J Biochem Cell Biol; 2012 Nov; 44(11):2028-31. PubMed ID: 22842535
[TBL] [Abstract][Full Text] [Related]
53. An Autonomous Cannabinoid System in Islets of Langerhans.
Aseer KR; Egan JM
Front Endocrinol (Lausanne); 2021; 12():699661. PubMed ID: 34290671
[TBL] [Abstract][Full Text] [Related]
54. The endocannabinoid system in advanced liver cirrhosis: pathophysiological implication and future perspectives.
Baldassarre M; Giannone FA; Napoli L; Tovoli A; Ricci CS; Tufoni M; Caraceni P
Liver Int; 2013 Oct; 33(9):1298-308. PubMed ID: 23890208
[TBL] [Abstract][Full Text] [Related]
55. The evolving role of the endocannabinoid system in gynaecological cancer.
Ayakannu T; Taylor AH; Willets JM; Konje JC
Hum Reprod Update; 2015; 21(4):517-35. PubMed ID: 25958409
[TBL] [Abstract][Full Text] [Related]
56. Synthesis, in vitro and in vivo evaluation of 1,3,5-triazines as cannabinoid CB2 receptor agonists.
Yrjölä S; Sarparanta M; Airaksinen AJ; Hytti M; Kauppinen A; Pasonen-Seppänen S; Adinolfi B; Nieri P; Manera C; Keinänen O; Poso A; Nevalainen TJ; Parkkari T
Eur J Pharm Sci; 2015 Jan; 67():85-96. PubMed ID: 25447744
[TBL] [Abstract][Full Text] [Related]
57. The Endocannabinoid System as a Therapeutic Target in Glaucoma.
Cairns EA; Baldridge WH; Kelly ME
Neural Plast; 2016; 2016():9364091. PubMed ID: 26881140
[TBL] [Abstract][Full Text] [Related]
58. Perinatal maternal high-fat diet induces early obesity and sex-specific alterations of the endocannabinoid system in white and brown adipose tissue of weanling rat offspring.
Almeida MM; Dias-Rocha CP; Souza AS; Muros MF; Mendonca LS; Pazos-Moura CC; Trevenzoli IH
Br J Nutr; 2017 Nov; 118(10):788-803. PubMed ID: 29110748
[TBL] [Abstract][Full Text] [Related]
59. Ligand-Assisted Protein Structure (LAPS): An Experimental Paradigm for Characterizing Cannabinoid-Receptor Ligand-Binding Domains.
Janero DR; Korde A; Makriyannis A
Methods Enzymol; 2017; 593():217-235. PubMed ID: 28750804
[TBL] [Abstract][Full Text] [Related]
60. Role of lipids and lipid signaling in the development of cannabinoid tolerance.
Martin BR
Life Sci; 2005 Aug; 77(14):1543-58. PubMed ID: 15949820
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
